CYP2C19

Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response

J. A. Nastasi-Catanese, Padilla-Gutiérrez, J. R., Valle, Y., Ortega-Gutiérrez, F., Gallegos-Arreola, M. P., and Figuera, L. E., Genetic contribution of CYP2C9, CYP2C19, and APOE variants in acenocoumarol response, vol. 12, pp. 4413-4421, 2013.

Oral anticoagulants of the coumarin type have an inconveniently narrow therapeutic window, making their use difficult. In Mexico, genetic variables that participate in the heterogeneity of the therapeutic response remain poorly investigated. With the focus on warfarin, extensive pharmacogenomic studies have been performed, including those on the CYP450 family and APOE.

Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China

Z. F. Yang, Cui, H. W., Hasi, T., Jia, S. Q., Gong, M. L., and Su, X. L., Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China, vol. 9, pp. 1844-1851, 2010.

We examined the distribution of major allelic variants of CYP2C9 and CYP2C19 in the Mongolian population of China and compared it with that of other populations. The polymorphisms of CYP2C9 (including the CYP2C9*1, CYP2C9*2 and CYP2C9*3 alleles) and CYP2C19 (including the CYP2C19*1, CYP2C19*2 and CYP2C19*3 alleles) were analyzed in 280 healthy unrelated Chinese Mongolian subjects, using a PCR-RFLP assay.

Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women

C. Q. Gan, Wang, X. Y., Cao, Y. D., Ye, W. X., Liu, H., and Sun, Y. Y., Association of CYP2C19*3 gene polymorphism with breast cancer in Chinese women, vol. 10, pp. 3514-3519, 2011.

Cytochrome P450 (CYP) 2C19 metabolizes arachidonic acid to biologically active epoxyeicosatrienoic acids, which significantly promote proliferation of cancer cells in vitro and in vivo. We looked for a possible association between human CYP2C19*3 gene polymorphism and breast cancer in the Chinese Han population. In a Chinese Han case-control study of breast cancer patients (N = 600) and age- and gender-matched healthy controls (N = 600), we investigated polymorphism in the CYP2C19 gene by PCR-RFLP analysis.

Subscribe to CYP2C19